In breast cancer, estrogen receptor (ER) and progesterone receptor (PR) are crucial biomarkers, and their deficiency indicates the potential transformation of normal cells into cancer cells, as well as limitations in endocrine therapy and poor prognosis5–7. This evidence concerns the gene ESR1 and breast cancer.